KRAS G12V Peptide
KRAS G12V Peptide is a polypeptide and epitope derived from KRASG12V. KRAS G12V Peptide forms a stable, high-affinity peptide-HLA class I complex, which is processed and presented by tumor cells and can be recognized by specific TCR. KRAS G12V Peptide is applicable to research related to metastatic lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 1932689-39-8
- Formula: C40H73N11O11
- Molecular Weight:884.07
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
KRas G12V |
MHC I |
KRAS G12V peptide can be targeted by TCR-engineered CD8+ T cells, which mediate efficient, dose-dependent killing of KRASG12V+ tumor cells; among these, HLA-A*11:01-restricted TCRA11V exhibits faster killing kinetics, which correlates with higher abundance of cell-surface peptide-HLA complexes[1].
KRAS G12V Peptide (1 mM; 2 h pulsed, 16-24 h co-incubation) does not induce cytotoxic activity against KV2 peptide-loaded T2KO-A1101 cells in primary T cells transduced with KDA11-01 and KDA11-02 TCRs[2].
KRAS G12V Peptide (1 mM) does not induce detectable IFN-γ production in primary T cells transduced with KDA11-01 and KDA11-02 TCR[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:T2KO-A1101 antigen-presenting cells, KDA11-01/KDA11-02 TCR-transduced primary human T cells
-
Concentration:10-6 M (pulsed for 2 h)
-
Incubation Time:16-24 h (co-incubation with TCR-transduced T cells)
-
Result:Showed negligible cytotoxicity against T2KO-A1101 cells pulsed with KRAS G12V peptide KV2, with cytotoxicity percentages comparable to non-transduced PBMC controls.
Chemical Information
-
CAS No. 1932689-39-8
-
Molecular Weight 884.07
-
Formula C40H73N11O11
-
SMILES
O=C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C(C)C)C(NCC(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C(C)C)N
-
Sequence
Val-Val-Val-Gly-Ala-Val-Gly-Val-Gly-Lys
-
Sequence Shortening
VVVGAVGVGK
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Bear AS, et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature communications. 2021 Jul 16;12(1):4365. [Content Brief]
[2]. Zheng W, et al. Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through development. Oncology research. 2024;32(12):1837-1850. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
KRAS G12V Peptide Related Classifications
HY-P11356 Related Classifications
Powered by Bioz